Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF

Aim    Optimal combination therapy for chronic heart failure (CHF) currently implies the mandatory use of at least four classes of drugs: renin-angiotensin-aldosterone (RAAS) system inhibitors or angiotensin receptor blocker neprilysin inhibitors (ARNI); beta-adrenoblockers (BAB); mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Furthermore, many of these drugs are able to decrease blood pressure even to hypotension and alleviate tachycardia. This study focused on the relationship of 24-h blood pressure (BP) and heart rate (HR) with the prognosis for CHF patients with sinus rhythm and left ventricular ejection fraction (LV EF) <50 % as well as on suggesting possible variants of safe therapy for CHF depending on the combination of studied factors.
Material and methods    Effects of clinical data, echocardiographic parameters, 24-h BP, and heart rhythm (data from 24-h BP and ECG monitors) on the prognosis of 155 patients with clinically pronounced CHF, LV EF <50 %, and sinus rhythm who were followed up for 5 years after discharge from the hospital.
Results    The one-factor analysis showed that the prognosis of CHF patients was statistically significantly influenced by the more severe functional class (FC) III CHF compared to FC II, reduced LV EF (<35 %), a lower 24-h systolic BP (SBP) (<103 mm Hg), the absence of hypotensive episodes in daytime, a low variability of nighttime BP (<7.5 mm Hg), a higher 24-h HR (>71 bpm vs. <60 bpm), the absence of therapy with RAAS inhibitors + BAB, and a lower body weight index. The multi-factor analysis showed that more severe CHF FC, lower LV EF, and the absence of RAAS inhibitors + BAB therapy retained the influence on the prognosis. After eliminating the influencing factor of drug therapy, also a low SBP variability significantly influenced the prognosis. An additional analysis determined the following four groups of CHF patients with reduced heart systolic function according to mean 24-h HR and SBP: the largest group (38.1 % of all patients) with controlled HR (≤69 bpm), preserved SBP (>103 mm Hg), and the lowest death rate of 15.3 %; the group with increased HR (>69 bpm) but preserved SBP (30.3 % of all patients) where the death rate was 44.7 %, which was significantly higher than in the first group; the group with normal HR (≤69 bpm) but reduced SBP (≤103 mm Hg) (16.1 % of patients) where the death rate was 40 %, which was comparable with the second group and significantly worse than in the first group; and the group with both increased HR (>69 bpm) and reduced SBP (≤103 mm Hg) (15.5 % of patients), which resulted in the maximal risk of death (70.8 % of patients with CHF and LV EF <50 %), which was significantly higher than in the three other groups.
Conclusion    Low SBP (including 24-h SBP with reduced variability in day- and nighttime) in combination with high HR (including by data of Holter monitoring), low LV EF, more severe clinical course of CHF, and the absence of an adequate treatment with neurohormonal modulators (RAAS inhibitors and BAB) significantly increased the risk of death. Isolating four types of FC II-III CHF with sinus rhythm and EF <50% based on the combination of HR and BP identifies patients with an unfavorable prognosis, which will help developing differentiated therapeutic approaches taking into account clinical features.

1. Belenkov Yu.N., Mareev V.Yu. The treatment of congestive heart failure in XXI century: questions and lessons of evidence based medicine. Kardiologiia. 2008;48(2):6–16.

2. Mareev Yu.V., Mareev V.Yu. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors. Kardiologiia. 2021;61(6):4–10. DOI: 10.18087/cardio.2021.6.n1678

3. Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2021;77(6):772–810. DOI: 10.1016/j.jacc.2020.11.022

4. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083

5. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475

6. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet. 2020;396(10244):121–8. DOI: 10.1016/S0140-6736(20)30748-0

7. Rogoza A.N., Oszhepkova E.V., Tsagareshvili E.V., Gorieva Sh.B. Modern non-invasive methods of blood pressure measurement for the diagnosis of hypertension and evaluation of the effectiveness of antihypertensive therapy. Manual for doctors. -M.: Medika;2007. – 72 p. ISBN 978-5-98495-010-7

8. Kapanadze L.G., Gerasimova V.V., Mareev Yu.V., Rogoza A.N., Mareev V.Yu. Factors affecting the 5-year survival rate of patients with mild and moderate CHF: the role of the office blood pressure level and indicators of the daily blood pressure profile in the prognosis of the disease. Russian Heart Failure Journal. 2013;14(6):353–61.

9. Mareev V.Yu., Mareev Yu.V. Influence of Omega-3 PUFA on Noninvasive factors determining the risk of arrhYthmias eXcess and sudden cardiac death in patients with HFpEF with ischemic etiology (ONYX). Kardiologiia. 2020;60(10):86–98.DOI: 10.18087/cardio.2020.10.n1327

10. Kapanadze L.G., Petrukhina A.A., Nasonova S.N., Skvortsov A.A., Mareev V.Yu. The role of hypotension as a factor of unfavorable prognosis in patients with chronic heart failure. Kardiologiia. 2011;51(10):53–60.

11. Sessa F, Anna V, Messina G, Cibelli G, Monda V, Marsala G et al. Heart rate variability as predictive factor for sudden cardiac death. Aging. 2018;10(2):166–77. DOI: 10.18632/aging.101386

12. Bilchick KC, Fetics B, Djoukeng R, Gross Fisher S, Fletcher RD, Singh SN et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs’ Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). The American Journal of Cardiology. 2002;90(1):24–8. DOI: 10.1016/S0002-9149(02)02380-9

13. Arbolishvili G.N., Mareev V.Yu., Orlova Ya.A., Belenkov Yu.N. The relationship of various indicators of heart rate variability with the mechanism of death in patients with chronic heart failure and left ventricular systolic dysfunction. Russian Heart Failure Journal. 2006;7(4):172–8.

14. Willenheimer R. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426–35. DOI: 10.1161/CIRCULATIONAHA.105.582320

15. Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal. 2009;30(18):2186–92. DOI: 10.1093/eurheartj/ehp323

16. Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal. 2012;33(22):2813–20. DOI: 10.1093/eurheartj/ehs259

17. Bagriy AE, Schukina EV, Samoilova OV, Pricolota OA, Malovichko SI, Pricolota AV et al. Addition of Ivabradine to β-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study. Advances in Therapy. 2015;32(2):108–19. DOI: 10.1007/s12325-015-0185-5